UroGen Pharma (URGN) EBIT (2017 - 2026)

UroGen Pharma's EBIT history runs 10 years deep, the most recent figure standing at -$20.3 million for Q1 2026.

• Quarterly EBIT rose 45.11% year-over-year to -$20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108.2 million (changed 0.24% YoY) and the FY2025 annual result came in at -$124.9 million, down 29.01% from the prior year.
• EBIT was -$20.3 million for Q1 2026 at UroGen Pharma, down from -$19.1 million in the prior quarter.
• Across five years, EBIT topped out at -$13.5 million in Q3 2023 and bottomed at -$41.4 million in Q2 2025.
• A 5-year average of -$22.7 million and a median of -$20.3 million in 2022 frame the typical range for EBIT.
• Annual changes were most pronounced in 2024 — EBIT sank 89.32% — and 2026, when it surged 45.11%.
• UroGen Pharma's EBIT stood at -$20.3 million in 2022, then rose by 27.97% to -$14.6 million in 2023, then plunged by 89.32% to -$27.7 million in 2024, then jumped by 30.89% to -$19.1 million in 2025, then retreated by 6.01% to -$20.3 million in 2026.
• Business Quant data shows URGN's EBIT at -$20.3 million in Q1 2026, -$19.1 million in Q4 2025, and -$27.4 million in Q3 2025.